Tharimmune, Inc. financial data

Symbol
THAR on Nasdaq
Industry
Pharmaceutical Preparations
Location
1200 Route 22 East, Bridgewater, NJ
State of incorporation
DE
Fiscal year end
December 31
Former names
Hillstream BioPharma Inc. (to 9/12/2023)
Latest financial report
10-K - Q4 2024 - Mar 26, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 324 % -13.1%
Debt-to-equity 44.6 % +21.8%
Return On Equity -270 % -24.3%
Return On Assets -187 % -17.4%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 2.11M shares -82.1%
Common Stock, Shares, Outstanding 1.97M shares +123%
Entity Public Float 1.7M USD -56.4%
Common Stock, Value, Issued 198 USD +122%
Weighted Average Number of Shares Outstanding, Basic 1.3M shares +1389%
Weighted Average Number of Shares Outstanding, Diluted 1.3M shares +1389%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 6.39M USD +79.6%
General and Administrative Expense 6.04M USD +2.48%
Operating Income (Loss) -12.4M USD -31.5%
Nonoperating Income (Expense) 236K USD +73.5%
Net Income (Loss) Attributable to Parent -12.2M USD -30.9%
Earnings Per Share, Basic -9.41 USD/shares +91.2%
Earnings Per Share, Diluted -9.41 USD/shares +91.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 4.77M USD +77.5%
Assets, Current 3.72M USD -66%
Assets 3.72M USD -66%
Accounts Payable, Current 1.09M USD +19.9%
Accrued Liabilities, Current 1.32M USD +46.1%
Liabilities, Current 2.41M USD +33%
Liabilities 2.41M USD +33%
Retained Earnings (Accumulated Deficit) -36.9M USD -49.4%
Stockholders' Equity Attributable to Parent 1.31M USD -85.7%
Liabilities and Equity 3.72M USD -66%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -2.83M USD +18.5%
Net Cash Provided by (Used in) Financing Activities 317K USD -39.4%
Common Stock, Shares Authorized 250M shares 0%
Common Stock, Shares, Issued 1.97M shares +123%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -2.51M USD +14.7%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 4.77M USD +77.5%
Deferred Tax Assets, Valuation Allowance 10.2M USD +52.6%
Deferred Tax Assets, Gross 10.2M USD +52.6%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Additional Paid in Capital 38.3M USD +12.9%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 710K USD -14.6%
Interest Expense 15.1K USD -23.4%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%